Response by Sex in Patient-Centered Outcomes With Baroreflex Activation Therapy in Systolic Heart Failure.
Response by Sex in Patient-Centered Outcomes With Baroreflex Activation Therapy in Systolic Heart Failure.
复制标题
DOI：
10.1016/j.jchf.2021.01.012
复制
发表时间：
2021-06
期刊：
影响因子：
--
通讯作者：
Zannad F
中科院分区：
文献类型：
--
作者：
Lindenfeld J;Gupta R;Grazette L;Ruddy JM;Tsao L;Galle E;Rogers T;Sears S;Zannad F
本研究的目的是评估BeAT-HF（压力反射激活疗法治疗心力衰竭）试验中压力反射激活疗法（BAT）的疗效和安全性的性别差异。将患者按1：1随机分为两组，对照组仅接受指南指导的药物治疗（GDMT），BAT加GDMT治疗。在男性与女性中进行预先规定的亚组分析，包括6分钟步行距离（6 MWD）从基线至6个月的变化、使用明尼苏达心力衰竭生活问卷（MLWHQ）评估的生活质量（QoL）、纽约心脏协会（NYHA）功能分级和N末端B型利钠肽前体（NT-proBNP）。对53名女性和211名男性进行了评估。与男性相比，女性的基线NT-proBNP水平、6 MWD和NYHA功能III级症状受试者百分比相似，但MLWHQ评分较差（平均值62 ± 22 vs. 50 ± 24; p = 0.01）。从基线到6个月，BAT + GDMT相对于GDMT单独治疗的女性MLWHQ评分有显著改善（分别为-34 ± 27 vs. -9 ± 23; p < 0.01），6 MWD（44 ± 45 m vs. -32 118 m; p < 0.01），NYHA心功能分级改善（70% vs. 27%; p < 0.01），与男性相似，安全性无显著差异。接受BAT加GDMT的女性NT-proBNP显著降低（-43% vs. 7%，单独使用GDMT;差异-48%; p < 0.01），而在男性中，这种降低分别为-15% vs. 2%（差异-17%; p = 0.08），相互作用p值为0.05。BeAT-HF组女性的基线QoL比男性差，但BAT组在6 MWD、QoL和NYHA心功能分级方面的改善相似。女性NT-proBNP有显著改善，而男性则没有。（心力衰竭的压力反射激活疗法[BeAT-HF]; NCT 02627196）（J Am科尔心脏病HF 2021;9：430-8）
The aim of this study was to assess sex differences in the efficacy and safety of baroreflex activation therapy (BAT) in the BeAT-HF (Baroreflex Activation Therapy for Heart Failure) trial. Patients were randomized 1:1 to receive guideline-directed medical therapy (GDMT) alone (control group) or BAT plus GDMT. Pre-specified subgroup analyses including change from baseline to 6 months in 6-min walk distance (6MWD), quality of life (QoL) assessed using the Minnesota Living With Heart Failure Questionnaire (MLWHQ), New York Heart Association (NYHA) functional class, and N-terminal pro–B-type natriuretic peptide (NT-proBNP) were conducted in men versus women. Fifty-three women and 211 men were evaluated. Women had similar baseline NT-proBNP levels, 6MWDs, and percentage of subjects with NYHA functional class III symptoms but poorer MLWHQ scores (mean 62 ± 22 vs. 50 ± 24; p = 0.01) compared with men. Women experienced significant improvement from baseline to 6 months with BAT plus GDMT relative to GDMT alone in MLWHQ score (—34 ± 27 vs. —9 ± 23, respectively; p < 0.01), 6MWD (44 ± 45 m vs. —32 118 m; p < 0.01), and improvement in NYHA functional class (70% vs. 27%; p < 0.01), similar to the responses seen in men, with no significant difference in safety. Women receiving BAT plus GDMT had a significant decrease in NT-proBNP (—43% vs. 7% with GDMT alone; difference —48%; p < 0.01), while in men this decrease was —15% versus 2%, respectively (difference —17%; p = 0.08), with an interaction p value of 0.05. Women in BeAT-HF had poorer baseline QoL than men but demonstrated similar improvements with BAT in 6MWD, QoL, and NYHA functional class. Women had a significant improvement in NT-proBNP, whereas men did not. (Baroreflex Activation Therapy for Heart Failure [BeAT-HF]; NCT02627196) (J Am Coll Cardiol HF 2021;9:430–8)
登录
查看更多内容
影响因子：
39.3
作者：
McAlister, FA;Tu, JV;Armstrong, PW
通讯作者：
Armstrong, PW
影响因子：
18.2
作者：
Zile, Michael R.;Abraham, William T.;Little, William C.
通讯作者：
Little, William C.
影响因子：
24
作者：
Zile, Michael R.;Lindenfeld, Joann;Abraham, William T.
通讯作者：
Abraham, William T.
DOI：
10.1161/circheartfailure.112.972828
发表时间：
2013-03
期刊：
Circulation. Heart failure
影响因子：
--
作者：
Ho JE;Lyass A;Lee DS;Vasan RS;Kannel WB;Larson MG;Levy D
通讯作者：
Levy D
影响因子：
9.7
作者：
Brenyo, Andrew;Barsheshet, Alon;Goldenberg, Ilan
通讯作者：
Goldenberg, Ilan